Department of Pathogen Biology, School of Medicine, Nantong University, Nantong 226001, Jiangsu, People's Republic of China.
Department of Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, People's Republic of China.
Int Immunopharmacol. 2020 Apr;81:106222. doi: 10.1016/j.intimp.2020.106222. Epub 2020 Jan 30.
Hepatocellular carcinoma (HCC) is globally recognized as one of the most frequently occurring primary malignant liver tumors, making the identification of HCC biomarkers critically important. The protein MITD1 (Microtubule Interacting and Trafficking Domain containing 1) has been shown to interact with ESCRT-III and participates in cytokinesis, the last step in cell division. This is the first investigation into the expression of MITD1 and its prognostic value, potential biological functions and effects on the immune system in HCC patients.
The gene expression and clinicopathology analysis, enrichment analysis and immune infiltration analysis are based on data obtained from The Cancer Genome Atlas (TCGA), with additional bioinformatics analyses performed. The statistical analysis was conducted in R and immune responses of MITD1 expression in HCC were analyzed using TIMER and CIBERSORT. In addition, GEPIA, K-M survival analysis and data from the HPA were used to validate the outcomes.
Our results highlighted that MITD1 plays a key role as an independent prognostic factor in patients with HCC. MITD1 expression was associated with age, grade, stage and tumor status. GSEA revealed that MITD1 is closely correlated with cell cycle control via the NOTCH signaling pathway. CIBERSORT analysis revealed that the amount of NK cells decreased when MITD1 expression was high.
The identification of MITD1 as a new biomarker for HCC could help elucidate how changes in cytokinesis and the immune environment promote liver cancer development. With further analysis, MITD1 may be able to serve as a predictor for human HCC prognosis.
肝细胞癌（HCC）是全球公认的最常见的原发性恶性肝肿瘤之一，因此识别 HCC 生物标志物至关重要。蛋白质 MITD1（微管相互作用和运输结构域包含 1）已被证明与 ESCRT-III 相互作用，并参与胞质分裂，这是细胞分裂的最后一步。这是首次研究 MITD1 的表达及其在 HCC 患者中的预后价值、潜在生物学功能和对免疫系统的影响。
基于从癌症基因组图谱（TCGA）获得的数据进行基因表达和临床病理分析、富集分析和免疫浸润分析，并进行了额外的生物信息学分析。统计分析在 R 中进行，使用 TIMER 和 CIBERSORT 分析 HCC 中 MITD1 表达的免疫反应。此外，使用 GEPIA、K-M 生存分析和 HPA 数据验证结果。
我们的结果强调，MITD1 作为 HCC 患者的独立预后因素起着关键作用。MITD1 的表达与年龄、分级、分期和肿瘤状态有关。GSEA 表明 MITD1 与通过 NOTCH 信号通路的细胞周期控制密切相关。CIBERSORT 分析表明，当 MITD1 表达较高时，NK 细胞的数量减少。
将 MITD1 鉴定为 HCC 的新生物标志物可以帮助阐明细胞分裂和免疫环境的变化如何促进肝癌的发展。通过进一步分析，MITD1 可能能够作为人类 HCC 预后的预测因子。
